Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2000
- Registration Number
- NCT00280956
- Locations
- 🇺🇸
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in, San Diego, California, United States
Open-Label Natalizumab Safety Extension Study
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1615
- Registration Number
- NCT00276172
- Locations
- 🇺🇸
Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in, Cambridge, Massachusetts, United States
Safety and Tolerability of Repeat Courses of IM Alefacept
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT00233662
- Locations
- 🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇫🇷Hopital L'Archet II, Nice, France
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 345
- Registration Number
- NCT00168766
- Locations
- 🇨🇭
Kantonspital, St. Gallen, Switzerland
🇧🇪CUB Hôpital Erasme, Bruxelles, Belgium
🇳🇱Stichting MS Centrum, Nijemegen, Netherlands
Efficacy and Safety of BG00012 in MS
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 260
- Registration Number
- NCT00168701
- Locations
- 🇸🇪
MS Centrum, Molndal, Sweden
🇨🇿Faculty Hospital, Hradec Kralove, Czechia
🇨🇿General Teaching Hospital, Prague, Czechia
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 150
- Registration Number
- NCT00168740
- Locations
- 🇺🇸
Hoag Hospital, Newport Beach, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 329
- Registration Number
- NCT00168714
- Locations
- 🇺🇸
Kendle, Wilmington, North Carolina, United States
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00168727
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸Northwest Oncology and Hematology, Elk Grove Village, Illinois, United States
🇺🇸Medical Specialists of Fairfield, Fairfield, Connecticut, United States
AVONEX® Combination Trial - "ACT"
- Conditions
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 350
- Registration Number
- NCT00112034
- Locations
- 🇺🇸
MS Academic Coordinating Center, Cleveland, Ohio, United States
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
- Conditions
- First Posted Date
- 2005-04-12
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 44
- Registration Number
- NCT00107861
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States